qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Wisconsin, Madison
About this trial
The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.
Eligibility criteria
Qualifiers
Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule
Disqualifiers
Pregnancy or breastfeeding
Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
Patients with a physical or psychological condition that would impair study participation.
Trial design
Treatments tested in this trial
- qDSA Blood Flow Measurement
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Wisconsin, Madison
Lead sponsor
Siemens Medical Solutions
Collaborator
Source ClinicalTrials.gov